Abstract
Electron affinity as measured by the one-electron reduction potential, E17, is the major factor influencing radiosensitizing efficiency in vitro. RSU 1069 has an electron affinity (E17 = -398 mV) similar to misonidazole, however, the ability of this compound to sensitize hypoxic cells is considerably greater than that of misonidazole, e.g. 0.2 mM RSU 1069 gives an enhancement ratio of 2.2 compared to 1.5 for the same concentration of misonidazole. Radiosensitization studies with the MT tumour in vivo also showed RSU 1069 to be a more efficient sensitizer than misonidazole. An administered dose of only 0.08 mg g-1 RSU 1069 yielded an enhancement of 1.8 to 1.9 using tumour cell survival and tumour cure as end-points. The ability of RSU 1069 to potentiate the cytotoxic action of melphalan towards the MT tumour was also examined. RSU 1069 (0.08 mg g-1) given to mice 1 h before melphalan resulted in an enhancement of 3.0. In contrast, previous studies had shown with a series of nitroimidazoles including misonidazole that Ro 03-8799 was the most effective potentiating agent, but this only gave an enhancement of 2.3 at a 10-fold higher dose than RSU 1069. RSU 1069 is a compound of substantial promise both as a radiosensitizer and chemopotentiating agent and warrants further investigation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Adams, G., Ahmed, I., Sheldon, P. et al. Radiation sensitization and chemopotentiation: Rsu 1069, a compound more efficient than misonidazole in vitro and in vivo. Br J Cancer 49, 571–577 (1984). https://doi.org/10.1038/bjc.1984.91
Issue Date:
DOI: https://doi.org/10.1038/bjc.1984.91
This article is cited by
-
Synthesis of Anticancer Compounds, I, “Dual Function” Antitumor Agents Based on Bioreduction and DNA-Alkylation
Monatshefte für Chemie - Chemical Monthly (2007)
-
Targeting gene expression to hypoxic tumor cells
Nature Medicine (1997)
-
Hypoxia and drug resistance
Cancer and Metastasis Reviews (1994)
-
The experimental development of bioreductive drugs and their role in cancer therapy
Cancer and Metastasis Reviews (1993)
-
Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference toin vivo methods of evaluation
Cancer and Metastasis Reviews (1993)